Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 315,200 shares, a growth of 10.7% from the July 15th total of 284,700 shares. Based on an average trading volume of 53,800 shares, the days-to-cover ratio is currently 5.9 days.
Institutional Investors Weigh In On Belite Bio
An institutional investor recently bought a new position in Belite Bio stock. Armistice Capital LLC purchased a new stake in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 148,000 shares of the company’s stock, valued at approximately $6,761,000. Armistice Capital LLC owned about 0.50% of Belite Bio as of its most recent SEC filing. Institutional investors own 0.53% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on BLTE shares. HC Wainwright upped their target price on Belite Bio from $59.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Benchmark restated a “buy” rating and issued a $57.00 price objective on shares of Belite Bio in a research note on Tuesday, August 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Belite Bio in a research report on Thursday, June 20th.
Belite Bio Stock Up 0.1 %
NASDAQ:BLTE traded up $0.05 during trading hours on Friday, reaching $49.95. The company had a trading volume of 18,701 shares, compared to its average volume of 53,877. The stock has a 50-day moving average of $48.51 and a two-hundred day moving average of $45.02. Belite Bio has a one year low of $21.01 and a one year high of $50.66. The firm has a market capitalization of $1.49 billion, a PE ratio of -42.33 and a beta of -1.47.
Belite Bio Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
- Five stocks we like better than Belite Bio
- Using the MarketBeat Dividend Yield Calculator
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Invest in Small Cap Stocks
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.